535 related articles for article (PubMed ID: 25287436)
1. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation.
Liu YY; Chiang PH; Chuang YC; Lee WC; Cheng YT; Wang HJ
Ann Surg Oncol; 2015 May; 22(5):1612-7. PubMed ID: 25287436
[TBL] [Abstract][Full Text] [Related]
2. Definition of biochemical success following primary whole gland prostate cryoablation.
Levy DA; Ross AE; ElShafei A; Krishnan N; Hatem A; Jones JS
J Urol; 2014 Nov; 192(5):1380-4. PubMed ID: 24813344
[TBL] [Abstract][Full Text] [Related]
3. Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen.
Kovac E; ElShafei A; Tay KJ; Mendez M; Polascik TJ; Jones JS
J Endourol; 2016 Jun; 30(6):624-31. PubMed ID: 26915721
[TBL] [Abstract][Full Text] [Related]
4. Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: The important predictors of biochemical recurrence.
Chen PY; Chiang PH; Liu YY; Chuang YC; Cheng YT
Int J Urol; 2018 Jun; 25(6):615-620. PubMed ID: 29756298
[TBL] [Abstract][Full Text] [Related]
5. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW
J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694
[TBL] [Abstract][Full Text] [Related]
6. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence.
De La Taille A; Benson MC; Bagiella E; Burchardt M; Shabsigh A; Olsson CA; Katz AE
BJU Int; 2000 Feb; 85(3):281-6. PubMed ID: 10671882
[TBL] [Abstract][Full Text] [Related]
7. Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up.
Oishi M; Gill IS; Ashrafi AN; Lin-Brande M; Nassiri N; Shin T; Bove A; Cacciamani GE; Ukimura O; Bahn DK; Abreu ALC
Eur Urol; 2019 Feb; 75(2):208-214. PubMed ID: 30274702
[TBL] [Abstract][Full Text] [Related]
8. Predicting biopsy-proven prostate cancer recurrence following cryosurgery.
Caso JR; Tsivian M; Mouraviev V; Polascik TJ
Urol Oncol; 2012; 30(4):391-5. PubMed ID: 20826095
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
[TBL] [Abstract][Full Text] [Related]
10. Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation.
Nyame YA; Elshafei A; Greene DJ; Arora HC; Given RW; Tay KJ; Polascik TJ; Ross AE; Mouraviev VB; Lugnani F; Jones JS
J Endourol; 2017 May; 31(5):497-501. PubMed ID: 28437170
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of Oncological and Functional Outcomes Between Primary Whole-Gland Cryoablation and High-Intensity Focused Ultrasound for Localized Prostate Cancer.
Liu YY; Chiang PH
Ann Surg Oncol; 2016 Jan; 23(1):328-34. PubMed ID: 26088651
[TBL] [Abstract][Full Text] [Related]
12. Comparison of biochemical failure definitions for predicting local cancer recurrence following cryoablation of the prostate.
Pitman M; Shapiro EY; Hruby GW; Truesdale MD; Cheetham PJ; Saad S; Katz AE
Prostate; 2012 Dec; 72(16):1802-8. PubMed ID: 22618738
[TBL] [Abstract][Full Text] [Related]
13. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry.
Jones JS; Rewcastle JC; Donnelly BJ; Lugnani FM; Pisters LL; Katz AE
J Urol; 2008 Aug; 180(2):554-8. PubMed ID: 18550117
[TBL] [Abstract][Full Text] [Related]
14. Radical prostatectomy versus external-beam radiotherapy for localized prostate cancer: long-term effect on biochemical control-in search of the optimal treatment.
González-San Segundo C; Herranz-Amo F; Alvarez-González A; Cuesta-Álvaro P; Gómez-Espi M; Paños-Fagundo E; Santos-Miranda JA
Ann Surg Oncol; 2011 Oct; 18(10):2980-7. PubMed ID: 21431406
[TBL] [Abstract][Full Text] [Related]
15. Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model.
Spiess PE; Levy DA; Mouraviev V; Pisters LL; Jones JS
BJU Int; 2013 Aug; 112(4):E256-61. PubMed ID: 23469778
[TBL] [Abstract][Full Text] [Related]
16. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
17. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].
Chautard D; Cellier P; Dalifard I; Pabot du Chatelard P; Chaussis F; Vielle B; Soret JY; Passagot J; Courte C; Daver A
Prog Urol; 2002 Jun; 12(3):421-8. PubMed ID: 12189749
[TBL] [Abstract][Full Text] [Related]
18. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
19. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for biochemical recurrence after a tissue-ablative prostate-specific antigen <0.2 ng/mL.
Taussky D; Lambert C; Meissner N; Bahary JP; Delouya G
Brachytherapy; 2018; 17(5):794-798. PubMed ID: 30153914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
